BioSpace News Archive

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results. ViewRay will hold a conference call to discuss results on Thursday, July 30, 20

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) on July 9, 2020 indicating that Lipocine has regained compliance with Nasdaq’s minimum bid price for continued listing on the

Enzychem Lifesciences (KOSDAQ: 183490) today announced that it has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to COVID-19 pneumonia. A Phase 2 study for

The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.

Teva Announces Availability of ProAir ® Digihaler ® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD - First and Only Digital Rescue Inhaler with Built-In Sensors Now Available By Prescription to Patients in the U.S. - Companion App Provides Objective Inhaler Event Data, Including Peak Inspiratory Flow. This data may be used to facilitate Health Care Provider-Patient Communication

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020.

Henry Schein, Inc. (Nasdaq: HSIC) announced that it is accepting applications for the Global Product Donation Program, which provides a broad variety of health care products and supplies to selected medical and dental nonprofit organizations to support their efforts to expand access to care for underserved communities.

Company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment

Pear Therapeutics Announces First Participant Enrolled in Virtual Real-World Study of Adults with Chronic Insomnia Fully virtual study will enroll 350 participants to collect real-world data for people with chronic insomnia using Pear’s own decentralized clinical trial infrastructure Engagement, Adherence, Healthcare Utilization, Medication Utilization, Health Economic Impact, and Clinical Outcomes in Sleep, Depression and Anxiety in People w

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will host a key opinion leader (KOL) webinar on envafolimab for the treatment of sarcom